{"id":1660,"date":"2024-02-06T16:01:00","date_gmt":"2024-02-06T21:01:00","guid":{"rendered":"https:\/\/gaffel.co\/?p=1660"},"modified":"2025-12-19T10:22:31","modified_gmt":"2025-12-19T15:22:31","slug":"invima-agiliza-tramites-por-la-problematica-de-represamiento-de-solicitudes","status":"publish","type":"post","link":"https:\/\/gaffel.co\/en\/invima-agiliza-tramites-por-la-problematica-de-represamiento-de-solicitudes\/","title":{"rendered":"Invima speeds up procedures due to the problem of backlog of applications."},"content":{"rendered":"<p class=\"wp-block-paragraph\">The National Institute for Food and Drug Surveillance (INVIMA) has announced a comprehensive strategy to address a significant backlog of requests for medicines and biological products. The causes identified include delays in previous terms, cybersecurity attacks, modernization needs in the technological infrastructure and the expansion of budgetary capacities. As of April 2023, 27,904 requests with delays were registered, of which 26,049 date from 2016 to November 2023. To address this problem, INVIMA has outlined a short, medium and long-term work plan, with the aim of resolving 85% of the accumulated requests by June 2024, addressing medicines that are out of stock, at risk of supply and under monitoring.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This approach seeks to optimize INVIMA's efficiency and response capacity in the face of challenges that have affected the regular flow of approvals and procedures for pharmaceutical products in the country, thus helping to ensure the timely and safe supply of essential medicines.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Conoce cu\u00e1les son las estrategias y c\u00f3mo impactan en su gesti\u00f3n para mejorar el acceso a medicamentos esenciales, leyendo completa <a href=\"https:\/\/www.flipsnack.com\/CCA6559BDC9\/gaffel-news-edici-n-19-diciembre-2023\/full-view.html\" rel=\"nofollow noopener\" target=\"_blank\">nuestra noticia en Gaffel News<\/a>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Source:\u00a0<a href=\"https:\/\/consultorsalud.com\/estrategias-invima-frente-al-represamiento\/\" rel=\"nofollow noopener\" target=\"_blank\">Consultor Salud<\/a> <\/p>","protected":false},"excerpt":{"rendered":"<p>Invima's Strategies to Streamline its Processes Amidst the Backlog of Applications. Discover what they are and how they impact its management to improve access to essential medicines.<\/p>","protected":false},"author":1,"featured_media":1661,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","_joinchat":[],"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1660","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sin-categoria"],"_links":{"self":[{"href":"https:\/\/gaffel.co\/en\/wp-json\/wp\/v2\/posts\/1660","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/gaffel.co\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/gaffel.co\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/gaffel.co\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/gaffel.co\/en\/wp-json\/wp\/v2\/comments?post=1660"}],"version-history":[{"count":2,"href":"https:\/\/gaffel.co\/en\/wp-json\/wp\/v2\/posts\/1660\/revisions"}],"predecessor-version":[{"id":3879,"href":"https:\/\/gaffel.co\/en\/wp-json\/wp\/v2\/posts\/1660\/revisions\/3879"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/gaffel.co\/en\/wp-json\/wp\/v2\/media\/1661"}],"wp:attachment":[{"href":"https:\/\/gaffel.co\/en\/wp-json\/wp\/v2\/media?parent=1660"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/gaffel.co\/en\/wp-json\/wp\/v2\/categories?post=1660"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/gaffel.co\/en\/wp-json\/wp\/v2\/tags?post=1660"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}